GET DAILY SIGNALSPfizer (PFE) Q1 2026 Earnings Preview: Modest Revenue Growth Amid EPS Pressures
Key Takeaways
- Analysts expect Q1 2026 revenues of approximately $13.8 billion, up slightly from $13.7 billion in Q1 2025.
- Consensus adjusted EPS estimate is around $0.72-$0.74 per share, down about 20% year-over-year from $0.92 due to product mix shifts and cost pressures.
- Key growth drivers include oncology products like Padcev and Lorbrena, alongside strong demand for Vyndaqel and Prevnar vaccines.
- COVID-19 products (Comirnaty, Paxlovid) expected to contribute less, with further declines anticipated.
- Pfizer reaffirmed 2026 full-year guidance of $59.5-$62.5 billion in revenue and $2.80-$3.00 adjusted diluted EPS.
- Stock up over 7% year-to-date as of early May 2026, outperforming broader market amid defensive positioning.
Earnings Context and Why This Report Matters
Pfizer's Q1 2026 earnings, set for release before market open on May 5, 2026, followed by a conference call at 10:00 AM ET, arrive at a critical juncture for the company. After a strong Q4 2025 with revenues of $17.6 billion and adjusted EPS beating estimates, the focus has shifted to the transition away from COVID-era highs toward growth in non-COVID areas. In my view, the oncology and rare disease portfolios stand out as essential counters to declines in legacy products and waning COVID demand. This earnings release should provide updates on the cost realignment program targeting $4 billion in savings, as well as pipeline progress, all against the backdrop of industry challenges like U.S. pricing reforms from the Inflation Reduction Act (IRA). For investors like us, it will shed light on margin stability and how well the company is executing on its 2026 guidance in a volatile biotech environment.
What to Expect from Q1 Numbers
Wall Street is looking for Q1 2026 revenues of $13.8 billion, a modest 0.8% rise from $13.7 billion in Q1 2025, supported by operational gains in key segments but tempered by COVID product declines. The consensus for adjusted diluted EPS sits at $0.72 to $0.74, marking a roughly 20% drop from $0.92 a year earlier, driven by elevated R&D spending and IRA impacts on Medicare pricing. One thing that stands out are the oncology sales, expected to grow on Padcev and Lorbrena, alongside cardiovascular and rare disease strength from Vyndaqel, and vaccines where Prevnar should offset the RSV/Abrysvo ramp-up. Eliquis alliance revenues could see U.S. net price erosion due to IRA changes. Pfizer has a track record of beating EPS estimates lately—Q4 2025 came in at $0.66 against $0.57 expected—and post-earnings stock moves have averaged modest shifts, with beats generally supporting upside on pipeline hopes.
Market Sentiment Ahead of the Report
Heading into earnings, sentiment around PFE leans cautiously optimistic. Shares are up over 7% year-to-date through early May 2026, outperforming the S&P 500's strong performance, thanks to reaffirmed 2026 guidance and the steady $0.43 quarterly dividend. Analysts hold a consensus Hold rating with a $28.74 price target, suggesting room for upside. That said, risks loom if oncology uptake disappoints or if guidance faces adjustments amid loss of exclusivity (LOE) pressures and COVID normalization. Post-earnings volatility has historically averaged 3-5%, with beats lifting shares 1-4% in the session. I also checked this using Tickeron’s AI Screener to gauge how PFE stacks up technically against other pharma names.
Discovering Opportunities with Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener as a powerful tool for sifting through stocks and ETFs. It lets me filter based on technical patterns, fundamentals, trends, volatility, and AI signals across thousands of names, using criteria like industry, market cap, indicators, price patterns, and performance metrics. This approach uncovers trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual scans, helping inform data-driven choices for portfolios. I've found it particularly useful for spotting potential in sectors like pharmaceuticals, including names like PFE.
Looking Ahead: Guidance and What to Watch
Pfizer has reaffirmed its 2026 guidance, projecting revenues of $59.5-$62.5 billion and adjusted diluted EPS of $2.80-$3.00. This implies slight topline declines from 2025's $62.6 billion, but operational growth when excluding COVID and LOE effects—about $5 billion from COVID products, a $1.5 billion LOE hit, and 4% core growth. From what I see, investors should pay close attention to Q1 progress on cost savings from the realignment program, now aimed at multi-year efficiencies, and R&D spending guided at $10.5-$11.5 billion, with emphasis on oncology like Padcev expansions and Seagen integration, plus vaccines. Pipeline highlights include ASCO data on Lorbrena and next-gen candidates such as sigvotatug vedotin. Broader factors to monitor: IRA pricing effects on Eliquis and Vyndaqel, international uptake for Prevnar and Abrysvo, and potential tariff risks. Margin stability—holding steady with 2025 on gross and operating levels—and a ~15% tax rate will help shape the EPS path. Key dates ahead: Q2 earnings in August and the dividend ex-date on May 8. I'm watching these closely for signs of sustained execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PFE sees MACD Histogram just turned negative
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 30 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 195 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement